&nbsp;

olsp-fact-sheet-other-languages.zip

New

Sep 2025

Document

olsp-fact-sheet-2025-fr.pdf

New

Sep 2025

Document

olsp-fact-sheet-2025.pdf

New

Sep 2025

Regimen

NIVL+IPIL

Cancer Type:

Gastrointestinal,

Hepatobiliary / Liver / Bile Duct

Intent: Palliative

Drugs Used:

nivolumab (Compassionate),

ipilimumab (Compassionate)

Quick Link(s):

Regimen Monograph

Sep 2025

Regimen

NIVL+IPIL

Cancer Type:

Gastrointestinal,

Colorectal

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab plus Ipilimumab - MSI-H/dMMR Locally Advanced Unresectable or Metastatic Colorectal Cancer

New Drug Funding Program

Nivolumab plus Ipilimumab - MSI-H/dMMR Locally Advanced Unresectable or Metastatic Colorectal Cancer

Drugs Used:

nivolumab,

ipilimumab

Quick Link(s):

Regimen Monograph

Dec 2025

Regimen

NIVL(MNT)

Cancer Type:

Gastrointestinal,

Hepatobiliary / Liver / Bile Duct

Intent: Palliative

Drugs Used:

nivolumab (Unfunded)

Quick Link(s):

Regimen Monograph

Sep 2025

Regimen

NIVL(MNT)

Cancer Type:

Gastrointestinal,

Colorectal

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab plus Ipilimumab - MSI-H/dMMR Locally Advanced Unresectable or Metastatic Colorectal Cancer

Drugs Used:

nivolumab

Quick Link(s):

Regimen Monograph

Dec 2025

Document

OntarioCervicalScreeningProgramFactSheet-other-languages.zip

New

Nov 2025

Regimen

OXALRALT+ZOLB

Cancer Type:

Gastrointestinal,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Zolbetuximab - First-line Treatment of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

New Drug Funding Program

Raltitrexed - Metastatic Esophageal, Gastroesophageal Junction, or Gastric Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

Nov 2025

Document

OH-Indigenous-cancer-strategy_EN.pdf

New

Dec 2025

Document

OH-Indigenous-cancer-strategy_FR.pdf

New

Dec 2025

Document